About one-third of U.S. employer health plans are offering coverage of GLP-1 drugs for both diabetes management and weight loss, up from last year, according to a survey of global employers released on Thursday by the International Foundation of Employee Benefit Plans.
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing’s syndrome.
The U.S. Supreme Court rejected a bid by anti-abortion groups and doctors to restrict access to the abortion pill, handing a victory on Thursday to President Joe Biden’s administration in its efforts to preserve broad access to the drug.
The countdown to Cannes is on as agencies across the globe prepare for one of the most highly anticipated events of the year. Roberta Raduan, managing director, LATAM at Klick Health shares some of the notable trends she’s seeing in her first year judging at Cannes (serving on the Pharma jury), and Rich Levy, chief creative officer, who has judged multiple times, offers some thoughts on what makes the event unique.
Pfizer’s investigational Duchenne muscular dystrophy gene therapy, fordadistrogene movaparvovec, failed in a late-stage study to significantly improve motor function in patients versus placebo.
Junshi Biosciences and Coherus BioSciences unveiled data from the Phase III HEPATORCH study, showing that its PD-1 inhibitor Loqtorzi (toripalimab)—when used with bevacizumab—significantly improved survival in patients with advanced hepatocellular carcinoma.